Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 685Carcinoma, Non-Small-Cell Lung 328Neoplasms 170Breast Neoplasms 166Lung Neoplasms 158Urinary Bladder Neoplasms 157Neoplasm Metastasis 140Cholangiocarcinoma 113Ovarian Neoplasms 106Biliary Tract Neoplasms 95Lymphoma, Large B-Cell, Diffuse 73Nasopharyngeal Carcinoma 71Lymphoma 66Sarcoma 63Recurrence 62Gallbladder Neoplasms 61Carcinoma, Transitional Cell 56Triple Negative Breast Neoplasms 54Hodgkin Disease 52Colorectal Neoplasms 49Lymphoma, Non-Hodgkin 48Fallopian Tube Neoplasms 48Adenocarcinoma 45Bile Duct Neoplasms 40Carcinoma, Ovarian Epithelial 31Non-Muscle Invasive Bladder Neoplasms 30Uterine Cervical Neoplasms 28Carcinoma 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma of Lung 27

Interventions

spartalizumab 1sapropterin 1penpulimab 1niraparib 1anlotinib 1Taxes 1Leucovorin 1Ipilimumab 1IFL protocol 1Gemcitabine 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Adenocarcinoma Metastatic × Gemcitabine × Clear all
NCT06051851 2023-09-25

RCT-PAAG

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Recruiting
177 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡